Interferon-β1a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement

Résumé fourni par la source

Thrombotic microangiopathy (TMA) is a systemic disorder characterized by either thrombotic or nonthrombotic microvascular lesions, leading to microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ involvement.1 Atypical hemolytic uremic syndrome is characterized by a deficient regulation and therefore an hyperactivation of the alternative pathway of the complement leading to endothelial injury.1,2 More than 50% of patients with atypical hemolytic uremic syndrome have a proved mutation in the alternative pathway of the complement regulatory genes or other noncomplement related genes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.